Condition: Neuroendocrine Tumors · Lung Neuroendocrine Neoplasm · Thymus Neoplasms · Sponsor: Grupo Espanol de Tumores Neuroendocrinos
LEVEL trial aims to demonstrate the higher efficacy of 177Lu-edotreotide over everolimus in patients with well to moderately differentiated neuroendocrine tumors of the lung and thymus who require systemic therapy. It is hypothesized that 177Lu-edotreotide may significantly increase the progression-free survival (PFS) compared to everolimus in lung and thymic carcinoids.
This description comes directly from the study's public registry record.
Federico Nepote · +34934344412 · investigacion@mfar.net
Always discuss trial participation with your own doctor first.
| Antwerp University Hospital (UZA) | Edegem, Edegem, Belgium | Recruiting |
| UCL Saint-Luc | Brussels, Belgium | Recruiting |
| CHU Liège | Liège, Belgium | Recruiting |
| Hospital Center University Dijon Bourgogne (CHU Bourgogne) | Dijon, Dijon, France | Recruiting |
| Centre Hospitalier Universitaire (CHU) Bordeux | Bourdeaux, France | Recruiting |
| Lille University Hospital | Lille, France | Recruiting |
| Hôpital Edouard Herriot, Lyon | Lyon, France | Recruiting |
| Department of Nuclear Medicine, La Timone University Hospital, CERIMED, Aix-Marseille University, France | Marseille, France | Recruiting |
| Department of Digestive Oncology, CHU Saint Eloi, Montpellier, France/ ICM Cancer Institute at Montpellier | Montpellier, France | Recruiting |
| Centre Hospitalier Universitaire de Nantes | Nantes, France | Recruiting |
| I. Gustave Roussy, Paris | Paris, France | Recruiting |
| Azienda USL IRCCS Di Reggio Emilia | Reggio Emilia, Reggio Emilia, Italy | Recruiting |
+ 15 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05918302